Arkolith/Insider Trading/GTBP/Form 4

Wendel Bruce

DirectorGT Biopharma, Inc. (GTBP) · full profile →Form 4 · filed Oct 7, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 16, 2021Grant(A)348K—$0353K
Dec 22, 2020Buy(P)441$8.73—5K
Dec 22, 2020Buy(P)1K$8.87—5K
Nov 16, 2020Buy(P)3K$3.14—3K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 16, 2021Grant(A)50K—$050K

Transaction Codes

A
Grant / award
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001654954-21-010887) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for GT Biopharma, Inc.

Build

Ask your agent about GTBP insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001654954-21-010887"
Ask your agent
Use Arkolith to summarize insider buying and selling at GT Biopharma, Inc.
over the last 90 days and cite the filings.